MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

February 14, 2018

New research published today in The Lancet Infectious Diseases journal by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) provides strong evidence that a combination of two new drugs for tuberculosis (TB)—the world’s leading infectious disease killer—could be used to treat drug-resistant (DR-TB) forms of the disease.

December 18, 2017

The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) has filed a patent challenge in China to block Gilead’s patent application for the combination of two key oral hepatitis C medicines, sofosbuvir and velpatasvir.

September 02, 2016

As the United States and other member countries of the G20 meet in Hangzhou, China, September 4-5, Doctors Without Borders/Médecins Sans Frontières (MSF) is urging them to address the failures of medical research and development (R&D) to deliver medicines, vaccines and diagnostics that match the health needs of people around the world instead of only focusing on the most lucrative products.

March 21, 2016

New York/Geneva, March 21, 2016—Two years after two new drugs to treat tuberculosis (TB)—the first in over 50 years—were conditionally approved for use, only two percent of the 150,000 people who need them most have been able to access them, according to Doctors Without Borders’ new edition of DR-TB Drugs Under the Microscope.

June 19, 2015

Doctors Without Borders/Médecins Sans Frontières (MSF) has learned that the Chinese patent office has just denied Gilead Science’s request for a key patent on the hepatitis C drug sofosbuvir. This drug, together with other antivirals, is the backbone of several newer, more effective curative treatments for hepatitis C, yet is exorbitantly priced in many countries, restricting access for people who need it. Hepatitis C is a global public health crisis, with at least 150 million people living with the disease, and 350,000-500,000 people die each year from complications of it.

December 17, 2013

Tuberculosis (TB) and its drug-resistant forms are a global health threat to which children are particularly vulnerable.

May 05, 2013

A mobile MSF TB surgery mission has successfully completed surgery on six DR-TB patients in Yeravan, Armenia.

March 15, 2012

As TB cases in Armenia rise at an alarming pace, MSF is stepping up "patient-centered" treatment of the deadly disease.

Pages

February 14, 2018

New research published today in The Lancet Infectious Diseases journal by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) provides strong evidence that a combination of two new drugs for tuberculosis (TB)—the world’s leading infectious disease killer—could be used to treat drug-resistant (DR-TB) forms of the disease.

December 18, 2017

The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) has filed a patent challenge in China to block Gilead’s patent application for the combination of two key oral hepatitis C medicines, sofosbuvir and velpatasvir.

September 02, 2016

As the United States and other member countries of the G20 meet in Hangzhou, China, September 4-5, Doctors Without Borders/Médecins Sans Frontières (MSF) is urging them to address the failures of medical research and development (R&D) to deliver medicines, vaccines and diagnostics that match the health needs of people around the world instead of only focusing on the most lucrative products.

March 21, 2016

New York/Geneva, March 21, 2016—Two years after two new drugs to treat tuberculosis (TB)—the first in over 50 years—were conditionally approved for use, only two percent of the 150,000 people who need them most have been able to access them, according to Doctors Without Borders’ new edition of DR-TB Drugs Under the Microscope.

June 19, 2015

Doctors Without Borders/Médecins Sans Frontières (MSF) has learned that the Chinese patent office has just denied Gilead Science’s request for a key patent on the hepatitis C drug sofosbuvir. This drug, together with other antivirals, is the backbone of several newer, more effective curative treatments for hepatitis C, yet is exorbitantly priced in many countries, restricting access for people who need it. Hepatitis C is a global public health crisis, with at least 150 million people living with the disease, and 350,000-500,000 people die each year from complications of it.

December 17, 2013

Tuberculosis (TB) and its drug-resistant forms are a global health threat to which children are particularly vulnerable.

May 05, 2013

A mobile MSF TB surgery mission has successfully completed surgery on six DR-TB patients in Yeravan, Armenia.

March 15, 2012

As TB cases in Armenia rise at an alarming pace, MSF is stepping up "patient-centered" treatment of the deadly disease.

Pages